At what enterprise value was NUTRISENS acquired in 2021?

During the acquisition of NUTRISENS by SAGARD in 2021, the transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR.

What was the EV/EBITDA of NUTRISENS when it was acquired by SAGARD?

The estimated EV/EBITDA multiple for NUTRISENS is in the range of 10x - 18x.

When was NUTRISENS acquired by SAGARD?

NUTRISENS was acquired by SAGARD in 2021.

What was the revenue of NUTRISENS at the time of the deal?

The revenue of NUTRISENS at the time of the deal is estimated to be in the range of 50M - 100M EUR.

What was the EBITDA of NUTRISENS during the acquisition?

NUTRISENS's EBITDA is estimated to be in the range of 5M - 25M EUR.

How is the data for the NUTRISENS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NUTRISENS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/sagard-preempte-nutrisens-et-le-valorise-140-150-m-1284516

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaNUTRISENS

01/2021

NUTRISENS acquired by SAGARD

FRANCE Life Sciences / Nutrition & Dietary Supplements EV 100M - 350M EUR

Context

Sagard entered into exclusive negotiations to acquire a majority stake in Nutrisens, effectively preempting an auction process that had attracted ten funds and three industrial players. The transaction marks the exit of historical shareholder Evolem (family office of Bruno Rousset), which had built the group since 2007, and minority investor Unigrains (who held 30%). The management team is reinvesting alongside Sagard. To secure the deal quickly, Sagard arranged a unitranche financing facility with Idinvest Partners. The strategic plan aims to exceed EUR100 million in revenue in 2021 through new acquisitions and by expanding distribution into pharmacies.

NUTRISENS, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a level the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European specialist in clinical nutrition and "medical food". Founded in 2011, the group develops specific nutritional products for patients suffering from pathologies such as dysphagia (swallowing difficulties), malnutrition, or renal failure. It serves hospitals, nursing homes (EHPAD), and pharmacies. The group has a strong Corporate footprint in France and Spain.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with NUTRISENS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NUTRISENS by SAGARD are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: sagard